The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2021 | Targeted therapy for the treatment of follicular lymphoma
Loretta Nastoupil, MD, University of Texas MD Anderson Center, Houston, TX, gives an overview on when to use targeted therapy in the treatment of follicular lymphoma (FL), highlighting several novel agents and trials investigating this. Dr Nastoupil first mentions some findings from the AUGMENT study (NCT01938001), which investigated the use of lenalidomide plus rituximab in relapsed/refractory (R/R) indolent lymphoma. Dr Nastoupil then draws focus on novel therapeutic agents such as tazemetostat, parsaclisib, CAR-T therapy, and bispecific antibodies, and the role that these will play in the future of targeted therapy for FL. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA, 2021.
